Henry Schein (HSIC) Stock Looks Cheap On Cash Flow But Fair On Earnings

Henry Schein stock has logged a solid 1 year return, yet the current market price and the intrinsic value estimate from a Discounted Cash Flow (DCF) model point to a stock that may still be trading at a discount to its cash flow potential. At the same time, broader valuation checks suggest a more mixed picture rather than a clear bargain.

• The 1 year return of 28.7% highlights that Henry Schein shares have already rewarded investors, which can reduce the margin of safety if the market has priced in much of the good news.
• Expectations that Henry Schein can keep converting its dental and medical distribution position into steady cash flows may support the valuation, while any pressure on margins or cash flow timing could challenge the case that the current price leaves room for further upside.
• The company earns a mixed overall value score of 4 out of 6, which signals that some checks see Henry Schein as attractively priced while others point to a more fully valued stock.

The issue now is whether Henry Schein's share price around recent levels already reflects a fair view of its cash flow outlook or whether the intrinsic value estimate suggests there is still meaningful upside left.

Compare Henry Schein's valuation story with other potential ideas by scanning 45 high quality undervalued stocks, which our platform has already filtered for solid cash flows and balance sheet strength.

Is Henry Schein a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model here estimates what Henry Schein’s future cash generation could be worth today. On the latest twelve month numbers, Henry Schein produced free cash flow of about $503 million. The model assumes growing cash flows through the next stage, before settling into a more modest long term pattern.

On those assumptions, the DCF model points to an estimated intrinsic value of about $162 per share. Compared with the current market price, this implies the stock trades at roughly a 44.9% discount to the cash flow estimate. This indicates the market is valuing Henry Schein’s projected cash flows quite conservatively.

On this analysis, Henry Schein stock appears undervalued relative to the discounted cash flows used in the model.

Our Discounted Cash Flow (DCF) analysis suggests Henry Schein is undervalued by 44.9%. Track this in your watchlist or portfolio, or discover 45 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Henry Schein.

Where Does Henry Schein Sit on Earnings?

P/E is a useful cross check for Henry Schein because earnings are a key driver for a mature distributor with steady cash generation. On this yardstick, Henry Schein trades on a P/E of about 24.8x. That is slightly below the Healthcare industry average of 25.0x and above the peer group average of 21.1x, so the stock does not screen as an obvious outlier in either direction.

The fair P/E ratio implied by the model is 27.2x. This is only modestly higher than the current 24.8x. This suggests the market is applying a small discount relative to what the company’s profile would usually warrant. The gap is not wide enough to argue the stock is clearly cheap or expensive on earnings alone. It points instead to a valuation that is broadly aligned with the sector while allowing for company specific risks.

Overall, Henry Schein looks roughly fairly valued on its P/E multiple when set against both the modelled fair ratio and wider Healthcare benchmarks.

See what the numbers say about this price — find out in our valuation breakdown.

The Henry Schein Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the valuation puzzle for Henry Schein leaves off, by spelling out which assumptions on growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price on the Community page. Each Narrative is structured as a thesis about Henry Schein's business that can be tracked over time to see whether it continues to hold up.

Community views on Henry Schein are split between a margin and technology driven upside story and a more cautious take on execution risk and pricing pressure.

Bull case: 8% undervalued

"Investments in digital workflow, AI solutions, and integrated cloud-based practice management platforms are accelerating recurring SaaS revenues and client retention, positioning Henry Schein to benefit from the ongoing digital transformation of healthcare, which should support both revenue growth and improved margins."

Read the full Bull Case to see why Henry Schein could be undervalued

Bear case: 20% overvalued

"The value creation program targets more than $200 million in operating income improvements and includes large scale outsourcing and shared services, which introduces execution risk that could disrupt customer service and internal operations, putting pressure on revenue retention, G&A savings and the planned $125 million operating income run rate by the end of 2026."

Read the full Bear Case to see why Henry Schein could be overvalued

Do you think there's more to the story for Henry Schein? Head over to our Community to see what others are saying!

The Bottom Line

For Henry Schein, the Discounted Cash Flow (DCF) work points to an intrinsic value that sits well above the current share price, while the P/E view lines up closer to an about right market multiple. That mix fits with the broader, mixed valuation checks and suggests the stock may offer some valuation support, but not a clear cut bargain. The key question from here is whether Henry Schein can deliver on margin and cash flow expectations without stumbling on execution. This would determine whether the current discount reflects opportunity or a fair pricing of risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com